Innovative therapies to treat and cure
hepatitis B virus (HBV) and other viral diseases

The only Active Site Polymerase Inhibitor Nucleotide (ASPIN) in Development

Combining the ASPIN, ATI-2173, with a Nucleoside Analogue (NA), such as Tenofovir (TDF) or Entecavir (ETV), in a one-pill, once-a-day regimen could completely shut down HBV polymerase activity and viral replication, potentially curing HBV infected individuals

ATI-2173
Active Site Polymerase Inhibitor Nucleotide
ATI-2173
HBV
Hepatitis B virus affects 290 million + worldwide
HBV
HDV
Hepatitis delta virus co-infects 5-6% of HBV-infected persons
HDV

News

June 29, 2021
Arbutus Biopharma and Antios Therapeutics Announce Clinical Collaboration Agreement to Evaluate AB-729 in Combination with ATI-2173 in Subjects with Chronic Hepatitis B Virus Infection
June 23, 2021
Antios Therapeutics’ ATI-2173 Demonstrates Potent Antiviral Activity and Evidence of Off-Treatment Sustained Viral Suppression in Chronic HBV Patients
June 11, 2021
Antios Therapeutics Announces Poster Presentation at the Inaugural HBV-TAG Conference
SEE ALL NEWS

EASL presentations:

Pharmacokinetics of ATI-2173, a novel active site polymerase inhibitor nucleoside, in a Phase 1b clinical trial
VIEW
–
Phase 1 Results for ATI-2173, a novel active site polymerase inhibitor nucleotide, in HBV-infected subjects

VIEW

Improving lives through the
treatment of viral diseases